Opinion: Should every man 50-69 be screened for prostate cancer?

The American Cancer Society says that all men age 50-69 should now be screened for prostate cancer every two years using a blood test that measures a prostate-specific antigen (PSA). Black men, or those with a family history of prostate cancer, should begin annual testing at age 45. Men age 70-74 should discuss PSA testing with their physician, while men 75 and over should not be tested, according to the new guidelines . The recommendation to move to universal screening is a significant shift from the current practice of shared decision-making, where men are urged to discuss the pros and cons of prostate cancer screening with their physician. Roughly 40 per cent of U.S. men age 50-69 now routinely get a PSA test, and rates are lower in Canada. The new approach touted by the American Cancer Society, if broadly adopted, will undoubtedly result in more testing and more prostate cancer diagnoses. It also risks increasing unnecessary treatment, and over-treatment, including biopsies, surgeries and radiation. The side effects from these interventions can be serious, including erectile dysfunction, urinary incontinence, and bowel problems. Cancer organizations urge national panel to review outdated testing advice for prostate cancer It is not a given, either, that universal testing will actually reduce mortality – its ultimate goal. That’s why Canada, which is overdue for updated guidelines, should proceed cautiously. In Canada, an estimated 29,300 men were diagnosed with prostate cancer last year, and 5,300 died. Universal screening is fraught when discussing any cancer, and even more so with prostate cancer. Who should be tested and when is a debate that inflames passions, and triggers vigorous statistical debates, but for which there is no clear and simple answer. The American Cancer Society says its new guidelines were prompted by new European research showing greater benefits of universal screening. That 23-year study showed that one prostate cancer case is prevented for every 456 men screened, and that one death is averted for every 12 men diagnosed with prostate cancer. Opinion: It’s time to rethink prostate-cancer screening That is a pretty modest result for a test administered on a large scale for almost a quarter century. More importantly, the study didn’t say much about potential harms of screening. Nor do we know how much of the mortality reductions are attributable to screening as opposed to treatment. The new recommendations come from a single advocacy group, albeit a powerful one: the American Cancer Society. The U.S. Preventive Services Task Force, the government agency responsible for drafting guidelines, still holds that the benefits of universal screening do not outweigh the risks. The task force estimates that, for every 1,000 men screened, 100 cases of prostate cancer would be diagnosed, and up to half of those cases would never spread or be harmful. However, most would be treated anyhow and, as a result, 65 men would suffer from erectile dysfunction and/or urinary incontinence, and five men would die from prostate cancer even after treatment. The equivalent Canadian agency, the Canadian Task Force on Preventive Health Care, recommends that PSA screening not be done, a recommendation that has not changed since 2014, and which is out of step with clinical practice. More prostate cancer cases diagnosed at Stage 4 in recent years, study finds It’s noteworthy that the Canadian task force was scrapped earlier this year and replaced with the National Advisory Committee on Preventive Health Services. A coalition of cancer advocacy groups has urged the new committee to urgently update guidance on screening for prostate cancer. The question for the new advisory committee will be whether to embrace universal screening or stick with the current practice of shared decision-making. Again, caution is urged. More screening is not necessarily a good thing. It entails significant costs, financial and personal. The “early detection saves lives” mantra is powerful sloganeering. But the science is a lot more nuanced. Finding cancer earlier, when it is doing little or no harm, simply makes it look like a person is living longer, a phenomenon researchers call “lead time bias.” Watchful waiting (or active surveillance) – monitoring PSA levels but making no interventions – is the most useful approach in many cases. When cancer is suspected, it’s also important that follow-up tests be done, like repeat PSA tests, and even MRI scans. The harms of screening come from acting hastily. Every man wants to believe prostate screening has or will save their life. But it’s not a panacea. As Otis Brawley, a professor of oncology at Johns Hopkins University, and a global expert on cancer screening told STAT News: “A majority of people who were going to die from prostate cancer will still die from prostate cancer whether they are screened or not.”